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Background: Health care-associated pneumonia (HCAP) has been proposed as a new category
of respiratory infection. ATS/IDSA guidelines state that all patients with HCAP should receive
empirical therapy directed at multidrug-resistant pathogens. However, recent data from other
countries have reported a different picture of HCAP.
Methods: We conducted a retrospective observational study of patients with HCAP and CAP
who were hospitalized through the emergency department in JanuaryeDecember 2008 at Sam-
sung Medical Center, Seoul, Korea, and compared clinical characteristics, severity, distribution
of pathogen, and outcomes.
Results: In total, 345 patients hospitalized with pneumonia were eligible, 182 (52.8%) with
HCAP and 163 (47.2%) with CAP. Patients with HCAP had greater comorbidity and higher Pneu-
monia Severity Index (PSI) score (P < 0.001). Although Streptococcus pneumoniae was the most
frequently isolated pathogen in HCAP and CAP patients, the occurrence of potentially drug-
resistant pathogens (29.3% vs. 13.0%; PZ 0.044) and inappropriate initial antimicrobial treat-
ment (24.6% vs. 8.7%; P Z 0.032) were significantly higher in HCAP patients. Patients with
HCAP had a longer duration of hospital stay (13 [8e18] vs. 8 [6e12] days; P < 0.001), and higher
in-hospital mortality (19.2% vs. 7.4%; P Z 0.001). In a multiple logistic regression analysis,
however, in-hospital mortality was independently associated with higher PSI class (OR 2.82,
95% CI 1.19e6.70) and ICU admission (OR 15.37, 95% CI 3.58e66.05).
Conclusions: Severity of illness, rather than type of pneumonia, was the main predicting factor
for in-hospital mortality among patients with pneumonia hospitalized through the emergency
department.
ª 2010 Elsevier Ltd. All rights reserved.3410 3429; fax: þ82 2 3410 6956.
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Pneumonia is one of the most common infectious diseases
that require medical treatment and hospitalization.
Traditionally, pneumonia has been classified as either
community-acquired pneumonia (CAP) or nosocomial,
depending on where the infection developed. The
distinction between the two is considered relevant
because the risk factors for, microbiology of, and
outcomes associated with the two syndromes are distinct.
In recent years, however, the number of ambulatory and
non-hospitalized patients who are in regular contact with
the health care system has increased. As a result, patho-
gens traditionally thought to be confined to nosocomial
infections have actually been recovered in outpatients
who present to the hospital. Infections that occur among
outpatients in contact with the health care system have
been termed health care-associated infections.1 These
infections have various comorbid conditions, causative
pathogens, antimicrobial treatments, and outcomes that
resemble more closely nosocomial infection, despite their
outpatient setting.1e3
The designation of health care-associated pneumonia
(HCAP) was recently introduced to include an already-ill
population of nursing home residents, patients in long-term
care, and those undergoing same-day procedures, receiving
home- or hospital-based intravenous therapy, and under-
going dialysis.4 Compared with patients with CAP, those
with HCAP are often at greater risk for colonization and
infection with a wider spectrum of multidrug-resistant
(MDR) bacterial pathogens.5 Thus, the American Thoracic
Society (ATS)/Infectious Diseases Society of America (IDSA)
guidelines state that all patients with HCAP should receive
empirical therapy directed at MDR pathogens.4 However,
the definition of HCAP is still controversial and the results
of the published studies are based on different definitions
of HCAP. In addition, ATS/IDSA recommendation was based
on a limited number of studies available at the time,
primarily from the United States. Recent data from other
countries have shown a different picture of HCAP, with
a lower frequency of MDR pathogens.6e8
As a result, we sought to ascertain the epidemiology,
causative organisms, antibiotic susceptibility, and clinical
outcomes of HCAP in patients hospitalized through the
emergency department of a Korean teaching hospital.
Material and methods
This retrospective observational study was conducted at
Samsung Medical Center (a 1250-bed, university-affiliated,
tertiary referral hospital in Seoul, South Korea) between
January and December 2008. Over the study period, all
consecutive patients admitted to the hospital through the
emergency department with pneumonia were eligible.
Patients with hospital-acquired pneumonia (HAP) that
developed after being hospitalized for more than 72 h, or
within 10 days of leaving the hospital,9 were not included.
Additionally, immunocompromised patients, such as those
with neutropenia after chemotherapy or human immuno-
deficiency virus (HIV) infection, and those who had under-
gone transplantations were excluded.Patients with pneumonia were classified into HCAP and
CAP. We compared clinical characteristics, severity, distri-
bution of pathogens, and outcomes between the two
groups.
Permission was obtained from the institutional review
board of Samsung Medical Center to review and publish
information from the patients’ records. Informed consent
was waived because of the retrospective nature of the
study.
A clinical diagnosis of pneumonia required the presence
of new radiographic infiltrates and at least two of the
following clinical criteria: fever (>38 C) or hypothermia
(35 C), new cough with or without sputum production,
pleuritic chest pain, dyspnea, and altered breath sounds on
auscultation.10 HCAP was defined as a diagnosis of pneu-
monia in patients admitted to the hospital who met at least
one of the following criteria: (1) recent history of hospi-
talization for 2 days within 90 days of the infection, (2)
residence in a nursing home or long-term care facility, (3)
recent intravenous antibiotic therapy, chemotherapy, or
wound care within the past 30 days of the current infection,
and (4) attendance at a hospital or hemodialysis clinic.4
CAP was defined as a diagnosis of pneumonia in patients
who did not meet any of the criteria for HCAP.
Previous antibiotic therapy was defined as use of any
antibiotic for more than 48 h during the previous 90 days.
The severity of pneumonia was evaluated using the
prediction rule calculated according to the Pneumonia
Severity Index (PSI) and the CURB-65 criteria (confusion,
urea nitrogen, respiratory rate, blood pressure, age 65
years).11,12
An etiological diagnosis was considered when a respira-
tory pathogen was isolated from a usually sterile specimen,
Legionella pneumophila serogroup 1 or pneumococcal
antigen was detected in urine, the antibody titer for
atypical pathogen was increased to 4-fold or converted to
positive, or a predominant microorganism was isolated
from adequate sputa (>25 neutrophils and <10 squamous
epithelial cells per low-power field) or bronchial washing
fluids with compatible Gram staining. Methicillin-resistant
Staphylococcus aureus (MRSA), Pseudomonas species, Aci-
netobacter species, Stenotrophomonas maltophilia, and
extended-spectrum b-lactamase (ESBL) producing Enter-
obacteriaceae were considered to be potentially drug-
resistant (PDR) pathogens, as previously reported.8
The appropriateness of antibiotic therapy was analyzed
for all cases with an etiological diagnosis according to
susceptibility test criteria for lower respiratory tract
pathogens. Antibiotic therapy was classified as being inap-
propriate if the initially prescribed antibiotics were not
active against the identified pathogens, based on in vitro
susceptibility testing.13Statistical analysis
Data are presented as medians and interquartile ranges (25th
and 75th percentiles) for continuous variables and as number
(percentages) for categorical variables. Data were compared
using the ManneWhitney test for continuous variables and c2
or Fisher’s exact test for categorical variables. A multiple
logistic regression analysis was used to identify independent
Health care-associated pneumonia in Korea 1731prognostic factors associated with in-hospital mortality, as
measured by the estimated odds ratio (OR) with 95% confi-
dence intervals (CI). The in-hospital mortality was the
dependent variable and all potential risk factors at the 0.2
level in univariate analyseswere independent variables in the
forward stepwise multiple logistic regression model. In addi-
tion, for variables that were significant, two-way interaction
were considered for inclusion in the final model. The Hos-
mereLemeshow test was used to check goodness-of-fit of the
logistic regression. All tests were two-sided, and a P value of
less than 0.05was deemed to indicate statistical significance.
Data were analyzed using PASW Statistics 17 (SPSS Inc., Chi-
cago, IL, USA).
Results
Patient characteristics
During the study period, 456 consecutive patients with
pneumonia were hospitalized through the emergency
department. Of these patients, 50 with HAP and 61 immu-
nocompromised patients were excluded. Thus, in total, 345
patients hospitalized with pneumonia were eligible for this
study, consisting of 163 (47.2%) with CAP and 182 (52.8%)
with HCAP. The criteria for inclusion in the HCAP group are
shown in Table 1. Recent history of hospitalization within
90 days of the infection (65.9%) was the most common
criterion for HCAP.
The baseline characteristics of patients with HCAP and
CAP are presented in Table 2. HCAP was significantly more
common in male patients and had greater comorbidity. The
comorbid condition most significantly associated with HCAP
was cancer. The use of antibiotics within the previous 90
days was more frequent in patients with HCAP. However,
there was no significant difference in radiographic findings
or clinical parameters between the HCAP and CAP groups.
Moreover, there was no significant difference in CURB-65
scores, although patients with HCAP were more commonly
classified into high-risk PSI classes than were those with CAP.
Pathogen distribution
The bacterial pathogen of the pneumonia was identified in
65 (35.7%) patients with HCAP and in 46 (28.2%) with CAP
(PZ 0.137). The methods and results of etiologic diagnosis
are listed in Table 3. In patients with HCAP, blood for
culture were obtained in 182 (100%), pleural fluid in 15Table 1 Criteria of 182 patients with HCAPa
Criterion No. of patients (%)
Previous hospitalization
within 90 days
120 (65.9)
Chemotherapy in the 30
days before pneumonia
71 (39.0)
Prior antibiotic therapy in the
30 days before pneumonia
65 (35.7)
Nursing home residency 8 (4.4)
Hemodialysis 4 (2.2)
a Cases are duplicated.(8.2%), adequate sputum in 100 (54.9%), bronchoaleolar
lavage fluid in 17 (9.3%), bronchial washing fluid in 10 (5.5%)
and urine for antigen testing in 168 (92.3%). Corresponding
figures for patients with CAP were 162 (99.4%), 27 (16.6%),
70 (42.9%), 14 (8.6%), 13 (8.0%) and 156 (95.7%). The
distribution of pathogens for HCAP and CAP is shown in
Table 4. Overall, Streptococcus pneumoniae was the most
frequently isolated pathogens in HCAP and CAP patients.
However, patients with CAP (28/46, 60.8%) were significant
more likely to be infected with S. pneumoniae than those
with HCAP (25/65, 38.5%; P Z 0.020). Patients with HCAP
and CAP were not significantly different from each other in
terms of occurrence of S. aureus or its subtypes (methi-
cillin-susceptible S. aureus [MSSA] and MRSA). Gram-nega-
tive pathogens were isolated more frequently in patients
with HCAP than in those with CAP. The occurrence of PDR
pathogens was significantly higher in HCAP (19/65, 29.2%)
than CAP (6/46, 13.0%) patients (P Z 0.044).
Antimicrobial treatment and clinical outcomes
Antimicrobial treatment and outcomes of patients with
HCAP and CAP are shown in Table 5. Inappropriate initial
antimicrobial treatment was significantly higher in patients
with HCAP than in those with CAP (16/65, 24.6% vs. 4/46,
8.7%; P Z 0.032).
There was no significant difference regarding ICU
admission or the need for mechanical ventilation between
the groups. However, median length of hospital stay was
significantly longer in patients with HCAP than in those with
CAP (P < 0.001). The in-hospital mortality rate was higher
in patients with HCAP (PZ 0.001), although the early case-
fatality rate (<48 h) did not differ between the groups.
However, a multiple logistic regression analysis, adjusting
for underlying conditions including cancer and variables
related to severity of illness, identified that HCAP was not
an independent variable associated with in-hospital
mortality (P Z 0.306). When the interaction between
inappropriate antibiotic treatment and HCAP was included
in the final model, the interaction was not statistically
significant. Higher PSI class (OR 2.82 per risk class increase,
95% CI 1.19e6.70; PZ 0.019) and ICU admission (OR 15.37,
95% CI 3.58e66.05; P < 0.001) were independent predictors
of in-hospital mortality (HosmereLemeshow goodness-of-fit
test; P Z 0.901).
Discussion
To our knowledge, this is the first reported study to
compare the epidemiology and outcomes of CAP and HCAP
in Korea. We demonstrated that PDR pathogens were
significantly more likely to occur in patients with HCAP and
to be treated with an inappropriate antibiotic. However,
our multiple logistic regression analysis suggested that
markers of severity of illness (increased PSI risk class and
ICU admission), rather than type of pneumonia, were
important in predicting in-hospital mortality among
patients with pneumonia hospitalized through the emer-
gency department.
In a previous multicenter study of culture-positive
pneumonia in the United States, the incidence of HCAP
Table 2 Baseline characteristics of patents with HCAP and CAP.
Characteristics HCAP (n Z 182) CAP (n Z 163) P value
Age, years 65 (57e71) 67 (52e74) 0.907
Male 135 (74.2) 94 (57.7) 0.001
Comorbidity
Neoplastic disease 118 (64.8) 34 (20.9) <0.001
Chronic lung disease 44 (24.2) 32 (19.6) 0.309
Chronic heart disease 45 (24.7) 45 (27.6) 0.543
Chronic liver disease 1 (0.5) 4 (2.5) 0.193
Chronic kidney disease 7 (3.8) 7 (4.3) 0.833
Cerebrovascular disease 10 (5.5) 9 (5.5) 0.991
Diabetes 34 (18.7) 32 (19.6) 0.823
Autoimmune disease 2 (1.1) 1 (3.7) 0.156
Two or more comorbidities 68 (37.4) 37 (22.7) 0.003
Use of antibiotics within the previous 90 days 109 (59.9) 15 (9.2) <0.001
Radiographic findings
Bilateral lung involvement 87 (47.8) 74 (45.4) 0.655
Multiple lung involvement 128 (70.3) 100 (61.3) 0.079
Pleural effusion 45 (24.7) 51 (31.3) 0.174
Clinical parameters
Confusion 8 (4.4) 13 (8.0) 0.165
Respiratory failure (PaO2 < 60 mmHg or PaO2/FiO2 ratio < 300 mmHg) 80 (44.0) 61 (37.4) 0.218
Septic shock at onset 25 (13.7) 15 (9.2) 0.189
Bacteremia 10 (5.5) 4 (2.5) 0.153
Severity
CURB-65 score 1 (0e2) 1 (0e2) 0.274
CURB-65 score 3 19 (10.4) 14 (8.6) 0.560
PSI score 104 (83e119) 82 (60e110) <0.001
PSI high risk class IV 128 (70.3) 65 (39.9) <0.001
Data are presented as median (interquartile range) or number (%).
1732 H.K. Park et al.among patients who required hospitalization was found to
be lower than the incidence of CAP.5 However, in a subse-
quent study from the United States, Micek et al. found that
HCAP was more common than CAP among patients with
culture-positive pneumonia hospitalized in a large urban
teaching hospital.13 Recent data from other countries have
reported differing incidences (17.3e38.0%) of HCAP among
patients who required hospitalization.7e9 In our study,
HCAP accounted for 52.8% of all cases of community-onset
pneumonia. The high incidence of HCAP in our study could
have resulted from the substantial number of cancerTable 3 Methods and results of etiological diagnosis in patient
HCAP (n Z 182
Sterile specimen
Blood 5.5 (10/182)
Pleural fluid 13.3 (2/15)
Respiratory specimen
Adequate sputum 47.0 (47/100)
Bronchoalveolar lavage fluid 35.3 (6/17)
Bronchial washing fluid 10.0 (1/10)
Pneumococcal antigen test 5.9 (10/168)
Data are presented as % (number of diagnostic study/number of epispatients who required hospitalization or received chemo-
therapy, which was higher than in other reported studies.7,8
In addition, the comorbid condition most significantly
associated with HCAP was cancer in our study. In-hospital
mortality of cancer patients, regardless of type of pneu-
monia, was also higher than those of patients without
cancer in univariate analysis (20% vs. 9%, P Z 0.002). This
might contribute to the higher mortality in HCAP patients
than those of other study.7
In the largest retrospective microbiological study from
the United States, Kollef et al.5 reported that S. aureus wass with HCAP and CAP.
) CAP (n Z 163) P value
2.5 (4/162) 0.156
7.4 (2/27) 0.608
38.6 (27/70) 0.275
28.6 (4/14) 1.000
0.0 (0/13) 0.435
11.5 (18/156) 0.074
odes studied).
Table 4 Bacterial pathogen identified in patients with HCAP and CAP.
Bacterial pathogen HCAP (n Z 182) CAP (n Z 163) P value
Gram positive pathogens
S. pneumoniae 25 (38.5) 28 (60.8)
Streptococci other than S. pneumoniae 1 (1.5) 4 (8.7) 0.020
S. aureus 13 (20.0) 6 (13.0) 0.158
MSSA 8 5 0.338
MRSA 5 1
Other gram positive bacteria 0 0
Gram-negative pathogens
P. aeruginosa 9 (13.8) 2 (4.3) 0.119
Haemophilus influenza 4 (6.2) 2 (4.3) 1.000
Klebsiella pneumoniae 13 (13.8) 4 (8.7) 0.406
ESBL (þ) 7 4 0.091
ESBL () 6 0
Escherichia coli 3 (4.6) 0 0.265
Enterobacter species 1 (1.5) 1 (2.2) 1.000
Acinetobacter species 0 0
Other Gram-negative bacteria 3 (4.6) 1 (2.2) 0.641
Polymicrobial pathogens 12/65 (18.5) 6/46 (13.0) 0.446
No pathogen identified 117 (64.3) 117 (71.8) 0.137
Occurrence of PDR pathogen 19/65 (29.3) 6/46 (13.0) 0.044
Data are presented as number (%).
Potentially drug-resistant (PDR) pathogens include methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas species, Acine-
tobacter species, Stenotrophonas maltophilia, and extended-spectrum b-lactamase (ESBL) producing Enterobacteriaceae.
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pneumonia. In the HCAP patients, the etiology was very
similar to that in the HAP patients. Surprisingly, even in
CAP patients, S. pneumoniae was isolated in only 16.6%, as
compared with S. aureus in 25.5% and P. aeruginosa in
17.1%. In the present study, however, S. pneumoniae was
the most frequently isolated pathogen in HCAP and CAPTable 5 Antibiotic treatment and clinical outcomes of patients
Treatment and outcome HCAP (n
Initial antibiotic therapy
Monotherapy 27 (14.8
b-lactams 13
Quinolones 11
Other 3
Combined therapy 155 (85
b-lactams þ quinolones 66
b-lactams þ macrolides 70
b-lactams þ macrolide þ clindamycin 5
b-lactams þ clindamycin 5
Others 9
Inappropriate antibiotic treatment 16/65 (
ICU admission 44 (24.2
Need for mechanical ventilation 25 (13.7
Length of therapy 14 (9e1
Length of hospital stay 13 (8e1
Early case-fatality rate (<48 h) 4 (2.2)
In-hospital mortality rate 35 (19.2
Data are presented as number (%).patients, while PDR pathogens were isolated more
frequently in HCAP than CAP patients. These findings are
comparable to those of previous studies from outside the
United States.7,8 In a recent prospective observational
study conducted in Spain, Carratala` et al.7 reported that
S. pneumoniae was the most frequent causative organism
associated with HCAP and CAP, and accounted for 27.8%with HCAP and CAP.
Z 182) CAP (n Z 163) P value
) 32 (19.6)
13
16
3
.2) 131 (80.4)
32
91
3
3
2
24.6) 4/46 (8.7) 0.032
) 26 (16.0) 0.058
) 16 (9.8) 0.261
7) 14 (11e17) 0.943
8) 8 (6e12) <0.001
4 (2.5) 1.000
) 12 (7.4) 0.001
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P. aeruginosa were isolated more frequently in HCAP
patients, their overall prevalence was lower than in
epidemiological studies from the United States.5,13 In
a recent retrospective study of HCAP from Japan, S. pneu-
moniae was the most frequently isolated pathogen in HCAP
and CAP, while S. aureus and P. aeruginosa were isolated
more frequently in HCAP than CAP patients.8 Causes of
these differences could be associated with differences in
population composition, study design, and microbiological
methodology.14
In critically ill patients, inappropriate antibiotic treat-
ment is related to higher mortality.15e17 Micek et al.13
found that patients with HCAP were more likely to
receive inappropriate initial antibiotic treatment and have
a greater risk of in-hospital mortality. Zilberberg et al.18
also have reported that inappropriate antibiotic treat-
ment increased the risk of in-hospital mortality by nearly
three-fold in non-bacteremic HCAP patients. In the present
study, HCAP patients received inappropriate initial antibi-
otic treatment more frequently than CAP patients did.
Furthermore, in-hospital mortality tended to be higher in
patients who received inappropriate initial antibiotic
treatment in the univariate analysis (30% vs. 14%).
However, we could not confirm the contribution of inap-
propriate initial antibiotic treatment to in-hospital
mortality, after statistical adjustment for confounding
factors. This finding could be explained by the different
prevalence of MDR pathogens from that in previous reports
in the United States.5,13,18 In the present study, although
PDR pathogens were significantly more likely to occur in
patients with HCAP, the most frequent organism was
S. pneumoniae in both groups, as seen in studies from the
United Kingdom,6 Spain,7 and Japan.8 However, the
proportion of inappropriate initial antibiotic treatment was
markedly higher in HCAP patients infected with PDR path-
ogens than in those without (62% vs. 38%; P < 0.001),
consistent with a previous Japanese study.8 Thus, we
suggest that physicians dealing with patients with HCAP in
the emergency department should consider PDR pathogens
in selecting initial empirical antibiotic treatment.
Compared with patients who have CAP, patients with
HCAP are older and have more comorbidities, and,
therefore, a higher PSI score.7,9,19 Thus, it is possible that
in-hospital mortality is simply higher in more severely ill
patients, as well as in those who receive inappropriate
initial antibiotic treatment. The results of our multivar-
iate analysis support this, showing that greater disease
severity, demonstrated by higher PSI score, was associ-
ated independently with in-hospital mortality, along with
the need for ICU admission. However, CURB-65 did not
differ between the two types of pneumonia patients,
consistent with other studies.9,19 This finding may be
explained by the demographic characteristics of nursing
home residents and coexisting illnesses, which are
important in HCAP, but not included in the items of CURB-
65.11 Although neither model has been validated, nor
studied, in patients with HCAP, it seem that PSI score may
be better than CURB-65 in assessing severity of illness in
patients with HCAP.
There are several limitations to this study. First, given its
retrospective nature, there is always the possibility thatselection bias might have influenced the significance of our
findings. The data regarding how many patients with a high
risk of death had been refused ICU admission or further
management could not be extracted from the medical
records during the study period. Therefore, we could not
evaluate the influence of limitation of care decisions on the
outcome in this group. Furthermore, our study was from
a single institution with a comprehensive cancer center,
which had a large number of cancer patients receiving
chemotherapy, which could limit the generalizability of our
findings to other hospitals with smaller numbers of patients
with risk factors for HCAP. Second, the number of patients
with culture-positive results was relatively small. Thus, the
true incidence of PDR pathogens and their effects on
outcome may be underestimated. Third, evaluation for
atypical pathogens was inadequate because of incomplete
data in the medical records. Finally, we included only
patients with pneumonia that required hospitalization.
Thus, our results may not apply to patients treated as
outpatients.
In summary, we found that HCAP was more common than
CAP in a Korean teaching hospital. PDR pathogens were
significantly more likely to occur in patients with HCAP and
to receive inappropriate antibiotic treatment. Although
patients with HCAP had more severe disease, longer
hospital stays and higher mortality rates, severity of illness,
rather than type of pneumonia, was the main predicting
factor for in-hospital mortality among patients with pneu-
monia hospitalized through the emergency department.Acknowledgements
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